BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1937495)

  • 1. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
    Frödin JE; Faxas ME; Hagström B; Lefvert AK; Masucci G; Nilsson B; Steinitz M; Unger P; Mellstedt H
    Hybridoma; 1991 Aug; 10(4):421-31. PubMed ID: 1937495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
    Fagerberg J; Frödin JE; Wigzell H; Mellstedt H
    Cancer Immunol Immunother; 1993 Sep; 37(4):264-70. PubMed ID: 8348565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients.
    Herlyn D; Harris D; Zaloudik J; Sperlagh M; Maruyama H; Jacob L; Kieny MP; Scheck S; Somasundaram R; Hart E
    J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):303-11. PubMed ID: 8061902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the anti-idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits.
    Comacchio RM; Bradley J; Hohmann AW
    Immunol Cell Biol; 1996 Feb; 74(1):72-80. PubMed ID: 8934657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?
    Fagerberg J; Frödin JE; Ragnhammar P; Steinitz M; Wigzell H; Mellstedt H
    Cancer Immunol Immunother; 1994 Mar; 38(3):149-59. PubMed ID: 8124683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of cancer patients' immune responses by anti-idiotypic antibodies.
    Herlyn D; Wettendorff M; Koprowski H
    Int Rev Immunol; 1989; 4(4):347-57. PubMed ID: 2519932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the "internal image of the antigen" (ab2).
    Mellstedt H; Frödin JE; Biberfeld P; Fagerberg J; Giscombe R; Hernandez A; Masucci G; Li SL; Steinitz M
    Int J Cancer; 1991 May; 48(3):344-9. PubMed ID: 2040527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
    Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
    Cancer Immunol Immunother; 1996 Feb; 42(2):81-7. PubMed ID: 8620524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients.
    Birebent B; Koido T; Mitchell E; Li W; Somasundaram R; Purev E; Hoey D; Mastrangelo M; Maguire H; Harris DT; Nair S; Cai E; Herlyn D
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R27-33. PubMed ID: 11768621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
    Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
    Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.
    Wettendorff M; Iliopoulos D; Tempero M; Kay D; DeFreitas E; Koprowski H; Herlyn D
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3787-91. PubMed ID: 2786203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody CO17-1A.
    Herlyn D; Ross AH; Iliopoulos D; Koprowski H
    Eur J Immunol; 1987 Nov; 17(11):1649-52. PubMed ID: 3500066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of anti-antiidiotypic IgE antibodies obtained from an IgE monoclonal antibody specific for a 26-kilodalton Schistosoma mansoni antigen.
    Velge-Roussel F; Verwaerde C; Grzych JM; Auriault A; Capron A
    J Immunol; 1989 Apr; 142(7):2527-32. PubMed ID: 2494262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-idiotype immunization of cancer patients: modulation of the immune response.
    Herlyn D; Wettendorff M; Schmoll E; Iliopoulos D; Schedel I; Dreikhausen U; Raab R; Ross AH; Jaksche H; Scriba M
    Proc Natl Acad Sci U S A; 1987 Nov; 84(22):8055-9. PubMed ID: 3500471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific detection of antibodies in cancer patients following immunotherapy with anti-idiotype.
    Wettendorff M; Iliopoulos D; Schmoll E; Koprowski H; Herlyn D
    J Immunol Methods; 1989 Jan; 116(1):105-15. PubMed ID: 2783712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-idiotype cancer vaccines: pre-clinical and clinical studies.
    Herlyn D; Benden A; Kane M; Somasundaram R; Zaloudik J; Sperlagh M; Marks G; Hart E; Ralph C; Wettendorff M
    In Vivo; 1991; 5(6):615-23. PubMed ID: 1810448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
    Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
    Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.
    Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H
    Cancer Res; 1995 May; 55(9):1824-7. PubMed ID: 7728746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies.
    Frödin JE; Lefvert AK; Mellstedt H
    Cell Biophys; 1992; 21(1-3):153-65. PubMed ID: 1285327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
    Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
    Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.